We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+10.47%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$850M
AUM Growth
-$111M
Cap. Flow
-$61.2M
Cap. Flow %
-7.2%
Top 10 Hldgs %
87.63%
Holding
26
New
2
Increased
1
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$74.6M
2
UPB
Upstream Bio Inc
UPB
+$51.3M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$5.21M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$117M
2
IRON icon
Disc Medicine
IRON
+$47M
3
ANNX icon
Annexon
ANNX
+$19.7M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$8.32M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$576K

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$632K 0.07%
2,750,151
– –
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q4 2024 Portfolio in Review

As of Q4 2024, Bain Capital Life Sciences Investors held 26 positions worth $850M, down 12% from $961M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $61.2M in Q4 2024, reducing 5 holdings. Its largest reduction was Nuvalent, cutting an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Olema Pharmaceuticals worth $43.6M.

  • Bain Capital Life Sciences Investors's largest Q4 2024 buy was Olema Pharmaceuticals: 7,470,214 shares worth $43.6M.
  • Bain Capital Life Sciences Investors added most to NewAmsterdam Pharma in Q4 2024, an estimated $5.21M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $117M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $850M portfolio in Q4 2024.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 0 in Q4 2024.
  • Bain Capital Life Sciences Investors's portfolio value fell 12% quarter-over-quarter to $850M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2024, filed 14 Feb 2025.